PHARMAC and statins
Bennett, W.; McNee, W.
New Zealand Medical Journal 111(1077): 439-440
1998
ISSN/ISBN: 0028-8446 PMID: 9861928 Document Number: 486774
Document emailed within 1 workday
Related Documents
2003: Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins Prescrire International 12(66): 143-148Metcalfe, S.; Moodie, P.; Davies, A.; McNee, W.; Dougherty, S. 2005: PHARMAC responds on salbutamol New Zealand Medical Journal 118(1221): U1644
Grocott, R.; Metcalfe, S.; Moodie, P. 2006: PHARMAC and erythropoietin for cancer patients New Zealand Medical Journal 119(1236): U2039
Haddad, P. 1999: PHARMAC complicates treatment of glaucoma New Zealand Medical Journal 112(1099): 434
Baber, W.J.; Neeff, M. 2008: Ciproxin HC eardrops application for funding--and response from PHARMAC New Zealand medical journal 121(1281): 111-2; author reply 112-4
Metcalfe, S.; Wilkinson, T.; Rasiah, D. 2006: PHARMAC responds on agents to prevent osteoporotic fractures New Zealand Medical Journal 119(1230): U1895
Milne, R.; Wonder, M. 2011: Response to PHARMAC on Access to new medicines in New Zealand compared to Australia New Zealand Medical Journal 124(1347): 91-93
Metcalfe, S.; Moodie, P.; McNee, W. 2005: PHARMAC and tobacco control in New Zealand: two licensed funded options are already available New Zealand medical journal 118(1217): U1544; author reply U1544; discussion U1544
Grocott, R.; Metcalfe, S. 2012: PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric New Zealand Medical Journal 125(1358): 89-90
Grocott, R.; Metcalfe, S.; Alexander, P.; Werner, R. 2013: Assessing the value for money of pharmaceuticals in new Zealand--PHARMAC's approach to cost-utility analysis New Zealand Medical Journal 126(1378): 60-73
Sadzot, B.; Hans, G.; Bottin, P.; Moonen, G. 2003: Statins for the brain? Revue Medicale de Liege 58(10): 621-627
Cheung, B.M.; Kumana, C.R. 2001: Dementia and statins Lancet 357(9259): 880; author reply 880-1
Császár, A. 2009: Hepatotoxicity of statins Orvosi hetilap 150(37): 1754-5; author reply 1755
Aznaouridis, K.; Masoura, C.; Vlachopoulos, C.; Tousoulis, D. 2019: Statins in Stroke Current Medicinal Chemistry 26(33): 6174-6185
Christie, B. 1999: Statins being prescribed for those "least in need" BMJ 318(7187): 827
Neau, J.P.; Moumy, H.; Mathis, S.; Gil, R. 2005: Statins and prevention of strokes Revue Neurologique (Paris) 161(2): 237-244
Filip-Ciubotaru, F.; Foia, L.; Manciuc, C. 2009: Statins and oxidative stress Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 113(2): 315-321
Wehr, H.; Bednarska-Makaruk, M.łg. 2005: Will statins be used in dementia treatment? Neurologia i Neurochirurgia Polska 39(4): 318-323
Kariya, T.; Harada, K. 2011: Statins and antidyslipidemic agents Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 9): 194-198
Erikssen, J.; Madsen, S. 1997: Treatment of hypercholesterolemia with statins Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 117(22): 3216-3220